

KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

Antibodies and Vaccines as Drugs for COVID-19 (EK31)

January 13-14, 2021 • Virtual at your computer

Scientific Organizers: David P. Humphreys, Pierre Bruhns, Patrick C. Wilson and Esther Breij

Sponsored by 10x Genomics, BioLegend, Inc., Genentech, Inc., Genmab A/S and Merck & Co., Inc.

WEDNESDAY, JANUARY 13

Antibodies as Drugs for COVID-19 (7am Denver/Mountain Time Start)

***David P. Humphreys**, UCB Pharma, UK

Session Chair

***Esther Breij**, Genmab, Netherlands

Session Chair

Bo Barnhart, Abcellera Biologics Inc., Canada

Combating COVID-19: Identifying a Potential Drug Candidate for Human Testing in 90 Days

Christos Kyratsous, Regeneron Pharmaceuticals Inc, USA
Rapid Selection, Characterization and Clinical Development of Fully-Human Antibodies Against Emerging Infectious Diseases

Davide Corti, Vir Biotechnology, Switzerland

Cross-Neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody

X. Sunney Xie, Peking University, China

COVID-19 Neutralizing Antibodies Screened by Single Cell Genomics

Linqi Zhang, Tsinghua University, China

Human Neutralizing Antibodies Elicited by SARS-CoV-2 Infection

Xavier Saelens, Ghent University, Belgium

When Size Matters: A Broadly Neutralizing Single Domain Antibody to Prevent and Treat COVID-19

Michael Stumpp, Molecular Partners, Switzerland

Highly Potent Anti-SARS-CoV-2 Multivalent DARP in Therapeutic Candidates

Michael G. Ison, Northwestern/Celltrion, Inc., USA

Therapeutic Effect of Regdanvimab (CT-P59) in Patients with Mild to Moderate Symptoms of SARS-CoV-2 Infection

Natalia Freund, Tel Aviv University, Israel

Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors

Poster Session (11am Denver/Mountain Time Start)

THURSDAY, JANUARY 14

Vaccines as Drugs for COVID-19 (7am Denver/Mountain Time Start)

***David P. Humphreys**, UCB Pharma, UK

Session Chair

***Pierre Bruhns**, Institut Pasteur, France

Session Chair

Liise-anne Pirofski, Albert Einstein College of Medicine and Montefiore Medical Center, USA

The Challenges of a New Vaccine for a New Disease

Paul F. McKay, Imperial College, UK

Development of a Self-Amplifying RNA Vaccine for COVID-19

Andrea Carfi, Moderna, USA

Potent Vaccine Efficacy from mRNA-1273 Expressing SARS-CoV-2 Spike Protein Stabilized in the Prefusion Conformation

Alexander Muik, BioNTech, Germany

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Trevor RF Smith, Inovio, USA

Development of INO-4800, a DNA Vaccine for COVID-19

Sarah Catherine Gilbert, University of Oxford, UK

Development of ChAdOx1 nCoV-19 (AZD1222); Creating a Vaccine in a Pandemic Setting

Hanneke Schuitemaker, Janssen Vaccines & Prevention B.V., Netherlands

Janssen's Efforts in the Development of an Ad26 Based COVID-19 Vaccine

Susanne Rauch, CureVac, Germany

Development of the mRNA based SARS-CoV-2 Vaccine CVnCoV

Neeltje van Doremalen, NIAID, National Institutes of Health, USA

Intranasal Vaccination with ChAdOx1 nCoV-19 Results in Reduced Nasal Shedding and Lack of Lower Respiratory Tract Infection in SARS-CoV-2 Hamsters and Rhesus macaques

Networking Lounge (10am Denver/Mountain Time Start)